The initiation of coverage by a major financial institution like Goldman Sachs generally brings increased attention to a stock. However, the Neutral rating suggests that Goldman Sachs views VYX as fairly valued at its current price, implying limited upside or downside potential in the short term. The price target of $14 provides a benchmark for investors but does not suggest a significant change from current levels.